Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.
A design for the phase 3 ZILO-301 clinical trial, assessing the efficacy of zilovertamab plus ibrutinib for patients with mantle cell lymphoma, has been selected
Early relapsed appears to be an important predictor of survival among patients with mantle cell lymphoma.
Preclinical data show promise for the novel non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib in mantle cell lymphoma with resistance to both ibrutinib and venetoclax.
Researchers utilized the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to examine the prognostic impact on survival of pre-treatment health-related quality of life parameters for patients with newly diagnosed mantle cell lymphoma.
Phase 3 data suggest that concurrent treatment with ibrutinib and venetoclax yielded promising efficacy for patients with relapsed/refractory mantle cell lymphoma.
The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.
Yazeed Sawalha, MD, discusses how often autologous stem cell transplant is utilized in patients with mantle cell lymphoma.
Yazeed Sawalha, MD, discusses how socioeconomic factors may impact the completion of autologous stem cell transplant in patients with mantle cell lymphoma, as well as impacting clinical outcomes.
In an interview with CancerNetwork, Yazeed Sawalha, MD, discussed how socioeconomic factors can affect use of autologous stem cell transplant in multiple myeloma and lead to disparities.